Cargando…
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
BACKGROUND/AIMS: We aimed to evaluate the efficacy and safety of ustekinumab (UST) in the East-Asian population with moderate to severely active ulcerative colitis (UC). METHODS: This sub-analysis was conducted on data from East-Asian patients included in the UNIFI program (NCT02407236). UNIFI consi...
Autores principales: | Hisamatsu, Tadakazu, Kim, Hyo Jong, Motoya, Satoshi, Suzuki, Yasuo, Ohnishi, Yoshifumi, Fujii, Noriyuki, Matsushima, Nobuko, Zheng, Richuan, Marano, Colleen W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association for the Study of Intestinal Diseases
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566834/ https://www.ncbi.nlm.nih.gov/pubmed/33249802 http://dx.doi.org/10.5217/ir.2020.00080 |
Ejemplares similares
-
Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension
por: Abreu, Maria T, et al.
Publicado: (2022) -
Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies
por: Hibi, Toshifumi, et al.
Publicado: (2017) -
Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2022) -
Safety and efficacy of long‐term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2022) -
Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
por: Song, Eun Mi, et al.
Publicado: (2023)